JP2010539237A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539237A5
JP2010539237A5 JP2010525832A JP2010525832A JP2010539237A5 JP 2010539237 A5 JP2010539237 A5 JP 2010539237A5 JP 2010525832 A JP2010525832 A JP 2010525832A JP 2010525832 A JP2010525832 A JP 2010525832A JP 2010539237 A5 JP2010539237 A5 JP 2010539237A5
Authority
JP
Japan
Prior art keywords
solid
hcl salt
salt
xrpd pattern
hcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010525832A
Other languages
English (en)
Japanese (ja)
Other versions
JP5462168B2 (ja
JP2010539237A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/010884 external-priority patent/WO2009038757A2/en
Publication of JP2010539237A publication Critical patent/JP2010539237A/ja
Publication of JP2010539237A5 publication Critical patent/JP2010539237A5/ja
Application granted granted Critical
Publication of JP5462168B2 publication Critical patent/JP5462168B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010525832A 2007-09-19 2008-09-19 N−(5−tert−ブチル−イソオキサゾール−3−イル)−N’−{4−[7−(2−モルホリン−4−イル−エトキシ)イミダゾ[2,1−b][1,3]ベンゾチアゾール−2−イル]フェニル}ウレアを含む固形、その組成物、及びその用途 Active JP5462168B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99463507P 2007-09-19 2007-09-19
US60/994,635 2007-09-19
PCT/US2008/010884 WO2009038757A2 (en) 2007-09-19 2008-09-19 Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith

Publications (3)

Publication Number Publication Date
JP2010539237A JP2010539237A (ja) 2010-12-16
JP2010539237A5 true JP2010539237A5 (enExample) 2011-10-27
JP5462168B2 JP5462168B2 (ja) 2014-04-02

Family

ID=40468693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010525832A Active JP5462168B2 (ja) 2007-09-19 2008-09-19 N−(5−tert−ブチル−イソオキサゾール−3−イル)−N’−{4−[7−(2−モルホリン−4−イル−エトキシ)イミダゾ[2,1−b][1,3]ベンゾチアゾール−2−イル]フェニル}ウレアを含む固形、その組成物、及びその用途

Country Status (20)

Country Link
US (2) US8883783B2 (enExample)
EP (1) EP2201018B1 (enExample)
JP (1) JP5462168B2 (enExample)
KR (2) KR101572701B1 (enExample)
CN (1) CN101868465B (enExample)
AR (1) AR068528A1 (enExample)
AU (1) AU2008302744B2 (enExample)
BR (1) BRPI0816904B8 (enExample)
CA (1) CA2696776C (enExample)
CY (1) CY1117583T1 (enExample)
DK (1) DK2201018T3 (enExample)
ES (1) ES2573292T3 (enExample)
HR (1) HRP20160520T1 (enExample)
HU (1) HUE027982T2 (enExample)
IL (1) IL203926A (enExample)
MX (1) MX2010002295A (enExample)
PL (1) PL2201018T3 (enExample)
SI (1) SI2201018T1 (enExample)
TW (1) TWI437988B (enExample)
WO (1) WO2009038757A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101449057B1 (ko) * 2006-03-17 2014-10-10 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
EP2201018B1 (en) 2007-09-19 2016-03-16 Ambit Biosciences Corporation Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-ý7-(2-morpholin-4-yl-ethoxy)imidazoý2,1-b¨ý1,3¨benzothiazol-2-yl¨phenyl}urea, compositions thereof, and uses therewith
EP2596795A1 (en) * 2007-11-08 2013-05-29 Ambit Biosciences Corporation Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
CA2755976C (en) 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
SMT202000092T1 (it) 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011056939A1 (en) * 2009-11-05 2011-05-12 Ambit Biosciences Corp. Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives
CN103172648B (zh) 2011-12-20 2016-05-25 上海迪诺医药科技有限公司 三杂环衍生物、制备方法及应用
JP6116847B2 (ja) 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションAmbit Biosciences Corporation シクロデキストリンとの混合体を含有する錠剤
CN104513258B (zh) * 2013-09-26 2018-04-03 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
CA2976752C (en) 2015-02-20 2019-12-17 Daiichi Sankyo Company, Limited Method for treating cancer by combined use
CN109251181B (zh) * 2017-07-13 2021-08-31 广东东阳光药业有限公司 取代脲衍生物的盐及其在药物中的应用
WO2019018406A1 (en) * 2017-07-18 2019-01-24 Agrimetis, Llc METHODS OF PURIFYING L-GLUFOSINATE
CN110763544A (zh) * 2019-09-20 2020-02-07 南京聚谱检测科技有限公司 一种激光剥蚀样品制靶用快干可精磨粘合剂
CN111413421A (zh) * 2020-02-20 2020-07-14 广东电科院能源技术有限责任公司 污泥燃烧后灰尘中氯离子含量的测试方法、控制方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129432C (enExample) 1964-02-29
NL129626C (enExample) 1964-04-08
US3210370A (en) 1964-06-22 1965-10-05 Upjohn Co Process for preparing 2, 2'-methylene-bisareneimiazoles
FR2463774A1 (fr) 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
US4354970A (en) 1980-03-07 1982-10-19 Eastman Kodak Company Indoline coupled isothiazole azo dyes
JPS56138196A (en) 1980-03-29 1981-10-28 Yamanouchi Pharmaceut Co Ltd Imidazo (2,1-b)benzothiazole derivative
JPS5740492A (en) 1980-08-22 1982-03-06 Yamanouchi Pharmaceut Co Ltd Novel 2-phenylimidazo 2,1-b benzothiazole derivative
JPS57149288A (en) 1981-03-12 1982-09-14 Yamanouchi Pharmaceut Co Ltd Imidazo(2,1-b)benzothiazole derivative
US4464384A (en) * 1981-12-23 1984-08-07 Yamanouchi Pharmaceutical Co., Ltd. 2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them
JPS58109491A (ja) * 1981-12-23 1983-06-29 Yamanouchi Pharmaceut Co Ltd 2−フエニルイミダゾ〃2,1−b「あ」ベンゾチアゾ−ル誘導体
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
US4880824A (en) 1987-09-21 1989-11-14 Ortho Pharmaceutical Corporation Phenyl and benzoyl substituted imidazo-fused heterocyclic calcium channel blockers
EP0524055A1 (fr) 1991-07-19 1993-01-20 Synthelabo Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique
JPH05107705A (ja) 1991-10-17 1993-04-30 Konica Corp 新規な写真用カプラー
DK0571253T3 (da) 1992-05-19 1999-07-19 Adir Benzimidazolderivater med antidiabetisk og antiblodpladekoagulerende virkning
FR2699920B1 (fr) 1992-12-24 1995-02-10 Synthelabo Dérivés d'imidazo [2,1-b] benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique.
EP0607076A1 (fr) 1993-01-15 1994-07-20 Synthelabo Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
FR2700546B1 (fr) 1993-01-15 1995-02-17 Synthelabo Dérivés d'imidazo[2,1-b]benzoxazole-3-acétamide, leur préparation et leur application en thérapeutique.
JPH07291976A (ja) 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔2,1−b〕チアゾール誘導体
FR2722501B1 (fr) 1994-07-13 1996-08-09 Synthelabo Derives de 9h-imidazo(1,2-a)benzimidazole-3-acetamide, leur preparation et leur application en therapeutique
JP3178843B2 (ja) 1995-03-13 2001-06-25 日研化学株式会社 イミダゾチアゾール化合物
WO1998006724A1 (en) 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
US6127387A (en) 1996-12-10 2000-10-03 Thomas Jefferson University Use of CD4-binding small molecules to inhibit immune responses
FR2759698B1 (fr) 1997-02-20 1999-03-19 Synthelabo Derives de 1,4-diphenylimidazole-5-acetamide, leur preparation et leur application en therapeutique
JPH11106340A (ja) 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd Stat6活性化阻害剤
DE69831013T2 (de) 1997-12-22 2006-04-20 Bayer Pharmaceuticals Corp., West Haven Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
DE19905278A1 (de) 1999-02-09 2000-08-10 Bayer Ag Oxazolidinone und ihre Verwendung als antibakterielle Mittel
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001192386A (ja) 1999-10-29 2001-07-17 Meiji Seika Kaisha Ltd 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
DE10019714A1 (de) 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
AU7887501A (en) 2000-07-06 2002-01-21 Us Gov Health & Human Serv Tetrahydrobenzothiazole analogues as neuroprotective agents
US6696441B1 (en) 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
US20030143199A1 (en) 2001-10-09 2003-07-31 Carson Dennis A. Use of STAT-6 inhibitors as therapeutic agents
US20040127719A1 (en) 2002-03-08 2004-07-01 Kexin Yang Alpha-isocyanocarboxylate solid support templates, method of preparation and for using the same
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
BR0316506A (pt) 2002-11-25 2005-10-04 Pharmacia Corp Midas e ácidos heteroarilsulfonilmetil hidroxâmicos e sua aplicação como inibidores da protease
ES2320758T3 (es) 2002-12-18 2009-05-28 Mallinckrodt Inc. Sintesis de heteroaril acetamidas.
KR100647583B1 (ko) 2003-10-07 2006-11-17 삼성에스디아이 주식회사 이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
EP1684762A4 (en) 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
KR101449057B1 (ko) * 2006-03-17 2014-10-10 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
EP2201018B1 (en) 2007-09-19 2016-03-16 Ambit Biosciences Corporation Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-ý7-(2-morpholin-4-yl-ethoxy)imidazoý2,1-b¨ý1,3¨benzothiazol-2-yl¨phenyl}urea, compositions thereof, and uses therewith
EP2596795A1 (en) 2007-11-08 2013-05-29 Ambit Biosciences Corporation Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease

Similar Documents

Publication Publication Date Title
JP2010539237A5 (enExample)
JP2019514863A5 (enExample)
CN111225896B (zh) 免疫调节剂化合物
KR101919680B1 (ko) 신규한 피롤리딘 화합물 및 멜라노코르틴 수용체 아고니스트로서의 용도
JP2018193382A5 (enExample)
ES2905973T3 (es) Proceso para la preparación de diclorhidrato de 5-cloro-N2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-N4-[2-(propano-2-sulfonil)-fenil]-pirimidin-2,4-diamina
JP2017522276A5 (enExample)
JP2020535168A5 (enExample)
JP6787995B2 (ja) 細胞毒性ベンゾジアゼピン誘導体の調製方法
CA2543644A1 (en) Pyrazine derivatives and pharmaceutical use thereof
HRP20160520T1 (hr) ČVRSTI OBLICI KOJI SADRŽE N-(5-TERC-BUTIL-IZOKSAZOL-3-IL)-N'-{4-[7-(2-MORFOLIN-4-IL-ETOKSI)IMIDAZO[2,1-b]BENZOTIAZOL-2-IL]FENIL}UREJU, NJIHOVI SASTAVI I NJIHOVE UPORABE
JP2013539765A5 (enExample)
CN104768948A (zh) 作为选择性parp-1抑制剂的4-甲酰氨基-异二氢吲哚酮衍生物
JP7347852B2 (ja) 重水素化大環状化合物の調製方法
JP2007532560A5 (enExample)
JP2016509042A5 (enExample)
WO2011086541A1 (en) Novel polymorph of nilotinib monohydrochloride monohydrate
JP2016510768A5 (enExample)
CN109956906A (zh) 一种噁拉戈利关键中间体的制备方法
CN117164580A (zh) 一种kras g12c抑制剂的制备方法及其中间体
ES2733813T3 (es) Proceso para preparar una forma cristalina de lenalidomida
JP2015531354A5 (enExample)
EP3271351A1 (en) Novel polymorphic form x of nilotinib dihydrochloride hydrate
CN104072477B (zh) 伊马替尼的精制方法
WO2020046753A1 (en) Parp inhibitors for treating cancer and asthma